Table 3. Changes in sales price (RMB) of generic single and combined anticancer drugs after price adjustment.
| Drug sales price (RMB) | Before June, 2006 | After June, 2006 | Changes of price (%) |
|---|---|---|---|
| Single drugs | |||
| Vinorelbine (10 mg) | 303.40 | 223.06 | −26.50 |
| Docetaxel (20 mg) | 857.30 | 712.00 | −16.95 |
| Gemcitabine (0.20g) | 1,396.50 | 1,235.00 | −11.56 |
| Gemcitabine (1g) | 319.00 | 294.40 | −7.71 |
| Paclitaxel (30 mg) | 936.00 | 555.00 | −40.71 |
| Cisplatin (20 mg) | 37.10 | 32.50 | −12.40 |
| Combination regimens | |||
| NP | 2,649.80 | 1,974.48 | −25.49 |
| DC | 4,509.10 | 3,782.60 | −16.11 |
| GC | 4,929.60 | 4,431.40 | −10.11 |
| TP | 6,774.60 | 4,080.00 | −39.78 |
NSCLC, non-small cell lung cancer; NRCMS, new rural cooperative medical scheme; URBMI, urban resident basic medical insurance; UEBMI, urban employee basic medical insurance; PFFMC, publicly funded free medical care; PFPF, payment from personal funds; NA, those whose payment information was unavailable; NP, vinorelbine + cisplatin; DC, docetaxel + cisplatin; GC, gemcitabine + cisplatin; TP, paclitaxel + cisplatin or carboplatin. RMB at an exchange rate of 6.66 to US$ 1 on Aug 2016.